Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.36 |
| ▸ | MGAM | O43451 | 6/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | UGCG | Q16739 | 5/20 | 0.35 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.35 |
| ▸ | LCAT | P04180 | 2/20 | 0.35 |
| ▸ | LCT | P09848 | 3/20 | 0.34 |
| ▸ | SI | P14410 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23996530 | 1.00 | GBA1 (0.36) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL23996553 | 1.00 | GBA1 (0.36) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL23996561 | 1.00 | GBA1 (0.36) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL25420477 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL23996507 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL25420474 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL25420579 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL25420471 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL23996726 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 | |
| SCHEMBL23996736 | 0.94 | LCAT (0.37) | GBA1MGAMGAAUGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | claimed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| EP-4146624-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | Alectos Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| WO-2021224865-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2021-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174486-A1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | GBA1, GBA2, GAA | GBA1 1/4885MGAM 58/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.